Engineered Salmonella enterica serovar Typhimurium overcomes limitations of anti-bacterial immunity in bacteria-mediated tumor therapy

Engineered Salmonella enterica serovar Typhimurium overcomes limitations of anti-bacterial immunity in bacteria-mediated tumor therapy

Cancer is one of the leading causes of death in the industrialized world and represents a tremendous social and economic burden. As conventional therapies fail to provide a sustainable cure for most cancer patients, the emerging unique immune therapeutic approach of bacteria-mediated tumor therapy (...

Full description

Bibliographic Details
Main Authors: Sebastian Felgner, Dino Kocijancic, Michael Frahm, Ulrike Heise, Manfred Rohde, Kurt Zimmermann, Christine Falk, Marc Erhardt, Siegfried Weiss
Format: Article
Language:English
Published: Taylor & Francis Group 2018-02-01
Series:OncoImmunology
Subjects:
bacteria-mediated tumor therapy
e. coli
immunization
murine tumor model
salmonella typhimurium
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1382791

Internet

http://dx.doi.org/10.1080/2162402X.2017.1382791

Similar Items